Spruce Biosciences (SPRB)

Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with unmet medical needs. The company develops biologics and small-molecule product candidates aimed at addressing diseases with unmet medical needs and limited or no approved therapies. Its product candidate, TA-ERT for the treatment of Mucopolysaccharidosis Type IIIB (MPS IIIB), is a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase (rhNAGLU) intended as an enzyme replacement therapy for patients who lack rhNAGLU enzyme activity. TA-ERT is designed to restore rhNAGLU enzyme activity in the central nervous system following intracerebroventricular injection and promote clearance of heparan sulfate in the brain.

The Spruce Biosciences, Inc. Common Stock (SPRB) stock after-hours price today is $52.96, reflecting a +2.83% after-hours move since the market last closed. The company’s market capitalization stands at $145.76M, with a daily trading volume of $51.57K shares. For investors tracking price trends, Spruce Biosciences, Inc. Common Stock stock has ranged between $50.50 and $52.96 today. The previous closing price was $51.50.

Ready to get started? Follow the steps below, or read our guide on how to buy Spruce Biosciences stock on Kraken starting from $10.